Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginseng berry concentrate is a concentrated extract derived from the berry (fruit) of the Panax ginseng plant, distinct from the more commonly used root extract. Its major active constituents are ginsenosides, particularly ginsenosides Re and Rd, which are present in higher or unique amounts compared to ginseng root. Preclinical research indicates that ginseng berry concentrate exerts anti-proliferative and anti-inflammatory effects, notably in colorectal cancer models, primarily through cell cycle arrest (G2/M phase), induction of apoptosis, and downregulation of pro-inflammatory cytokines. It may also modulate immune responses by inhibiting Th17 cell differentiation. Ginseng berry concentrate is used and investigated as an herbal/dietary supplement, especially for its potential roles in immunostimulation, cancer chemoprevention, and anti-inflammatory effects. It is typically consumed orally. Evidence for clinical efficacy and safety remains limited. The product is not approved as a pharmaceutical drug and is primarily developed and marketed as a dietary supplement[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginseng berry concentrate.